(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 10.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Catalyst Pharmaceuticals's revenue in 2025 is $534,646,000.On average, 4 Wall Street analysts forecast CPRX's revenue for 2025 to be $68,301,450,064, with the lowest CPRX revenue forecast at $67,301,009,868, and the highest CPRX revenue forecast at $69,086,726,093. On average, 4 Wall Street analysts forecast CPRX's revenue for 2026 to be $77,069,633,866, with the lowest CPRX revenue forecast at $75,912,455,599, and the highest CPRX revenue forecast at $79,710,761,832.
In 2027, CPRX is forecast to generate $88,316,108,806 in revenue, with the lowest revenue forecast at $84,026,242,710 and the highest revenue forecast at $95,238,198,682.